Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2018 | 09-2018 | 06-2018 | 03-2018 | 12-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -67,657 | -52,953 | -28,596 | -13,424 | -51,013 |
| Depreciation Amortization | 24,697 | 1,014 | 590 | 286 | 1,121 |
| Income taxes - deferred | -1,548 | N/A | N/A | N/A | -11,435 |
| Accounts receivable | 204 | -1,813 | 164 | 491 | 892 |
| Other Working Capital | -1,955 | -6,184 | -2,502 | -3,029 | 234 |
| Other Operating Activity | -493 | 22,094 | 5,155 | 1,420 | 6,094 |
| Operating Cash Flow | $-46,752 | $-37,842 | $-25,189 | $-14,256 | $-54,107 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -817 | -595 | -502 | -16 | -232 |
| Investing Cash Flow | $-817 | $-595 | $-502 | $-16 | $-232 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -5,390 | -3,368 | -2,179 | N/A | N/A |
| Common Stock Issued | 100,107 | 100,107 | 24,815 | N/A | 5,495 |
| Other Financing Activity | 0 | 0 | 0 | 9,524 | 15 |
| Financing Cash Flow | $94,717 | $96,739 | $22,636 | $9,524 | $5,510 |
| Exchange Rate Effect | -92 | -86 | -93 | -17 | 83 |
| Beginning Cash Position | 92,164 | 92,164 | 92,164 | 92,164 | 140,910 |
| End Cash Position | 139,220 | 150,380 | 89,016 | 87,399 | 92,164 |
| Net Cash Flow | $47,056 | $58,216 | $-3,148 | $-4,765 | $-48,746 |
| Free Cash Flow | |||||
| Operating Cash Flow | -46,752 | -37,842 | -25,189 | -14,256 | -54,107 |
| Capital Expenditure | -817 | -595 | -502 | -16 | -269 |
| Free Cash Flow | -47,569 | -38,437 | -25,691 | -14,272 | -54,376 |